An immune enzyme quietly blocks cancer defense

Dendritic cells are sentinels of the immune system. They capture fragments of foreign proteins, including those from cancer cells, and present them to other immune cells to trigger a targeted attack. This process is called cross-presentation. The researchers, publishing in Science, found that the enzyme CARM1 inhibits this cross-presenting function.

CARM1 is an epigenetic enzyme, a protein that alters gene activity without changing the underlying DNA sequence. In dendritic cells, CARM1 was found to suppress the expression of genes required for effective cross-presentation. When CARM1 is active, the sentinel cells become less capable of recognizing and transmitting cancer signals to the rest of the immune system.

A potential new target for cancer treatment

If CARM1 dampens immune responses to cancer, it becomes a rational drug target. Inhibitors of CARM1, currently in early development, could restore cross-presentation capacity and allow immune cells to more effectively detect tumors. In mouse models, CARM1 inhibition led to stronger immune responses against cancer cells.

From a longevity perspective, there is an additional angle worth noting. Immune aging, or immunosenescence, is characterized by declining dendritic cell function in older individuals. Whether CARM1 activity contributes to that decline has not yet been studied, but the mechanistic link warrants investigation.

Where the evidence currently stands

The study was conducted primarily in mouse models and cell systems. Whether CARM1 inhibition will prove equally effective and safe in humans remains to be demonstrated through clinical trials. The researchers describe their findings as promising but preliminary. Clinical application in cancer patients lies some way ahead.

Read the original article